Shigella causes high morbidity and mortality worldwide, but there is no licensed vaccine for
shigellosis yet. We evaluated the safety and immunogenicity of a formalin-inactivated whole …

We report the first community-based evaluation of Shigella flexneri 2a strain SC602, a live,
oral vaccine strain attenuated by deletion of the icsA (virG) plasmid virulence gene, given at …

Orally delivered, inactivated whole-cell vaccines are safe methods of inducing local and
systemic immunity. To increase surface proteins associated with adherence and invasion …

We evaluated the safety and immunogenicity of attenuated Shigella flexneri 2a vaccine
candidate CVD 1203, which harbors precise deletions in the plasmid gene virG and in the …

In previous trials, live invasive Escherichia coli-Shigella flexneri 2a hybrid vaccine candidate
EcSf2a-2, administered to adult volunteers as 3 doses of ca. 2× 109 colony forming units …

We conducted a phase I trial with healthy adults to evaluate WRSS1, a live, oral Δ virG
Shigella sonnei vaccine candidate. In a double-blind, randomized, dose-escalating fashion …

The Shigella flexneri 2a SC602 vaccine candidate carries deletions of the plasmid-borne
virulence gene icsA (mediating intra-and intercellular spread) and the chromosomal locus …

In double-blind trials in Bangladesh, 88 adults, and 79 children (8–10 years) were
randomized to receive either a single oral dose of 1× 104, 1× 105 or 1× 106CFU of SC602 …

Background Shigellosis persists as a public health problem worldwide causing~ 165,000
deaths every year, of which~ 55,000 are in children less than 5 years of age. No vaccine …

Studies were undertaken to manufacture a multivalent Shigella inactivated whole-cell
vaccine that is safe, effective, and inexpensive. By using several formalin concentrations …